相似文献
1
New anticoagulants for the prevention and treatment of venous thromboembolism.
Vasc Health Risk Manag. 2005;1(1):41-53. doi: 10.2147/vhrm.1.1.41.58936.
2
Clinical trials of new anticoagulants.
Vnitr Lek. 2006 Mar;52 Suppl 1:123-6.
3
[Prophylaxis and treatment of venous thromboembolism: the role of new antithrombotic drugs].
Recenti Prog Med. 2005 Apr;96(4):196-204.
4
New anticoagulants for venous thromboembolic disease.
Curr Opin Cardiol. 2005 Nov;20(6):502-8. doi: 10.1097/01.hco.0000179822.18695.32.
5
New anticoagulants for treatment of venous thromboembolism.
Circulation. 2004 Aug 31;110(9 Suppl 1):I19-26. doi: 10.1161/01.CIR.0000140901.04538.ae.
6
[Treatment and prevention of venous thromboembolic events: present and future antithrombotic agents].
Bull Acad Natl Med. 2003;187(1):85-96; discussion 96-7.
7
Short- and long-acting synthetic pentasaccharides.
J Intern Med. 2003 Oct;254(4):335-42. doi: 10.1046/j.1365-2796.2003.01226.x.
8
Treating patients with venous thromboembolism: initial strategies and long-term secondary prevention.
Semin Vasc Med. 2005 Aug;5(3):276-84. doi: 10.1055/s-2005-916167.
9
Treatment of venous thromboembolism: duration and new options.
Hematol J. 2004;5 Suppl 3:S24-8. doi: 10.1038/sj.thj.6200417.
10
Factor Xa inhibition in the prevention of venous thromboembolism and treatment of patients with venous thromboembolism.
Curr Opin Pulm Med. 2002 Sep;8(5):398-404. doi: 10.1097/00063198-200209000-00010.
引用本文的文献
1
Obstructive Sleep Apnea and Venous Thromboembolism: Unraveling the Emerging Association.
Cureus. 2023 Aug 30;15(8):e44367. doi: 10.7759/cureus.44367. eCollection 2023 Aug.
2
Acute Portal Vein Thrombosis Treated with Recombinant Human Soluble Thrombomodulin Combined with Antithrombin III.
Case Rep Med. 2020 Apr 13;2020:8268016. doi: 10.1155/2020/8268016. eCollection 2020.
本文引用的文献
1
Dose-response study of recombinant human soluble thrombomodulin (ART-123) in the prevention of venous thromboembolism after total hip replacement.
J Thromb Haemost. 2005 May;3(5):962-8. doi: 10.1111/j.1538-7836.2005.01251.x.
2
Is that it, then, for blockbuster drugs?
Lancet. 2004;364(9440):1100. doi: 10.1016/S0140-6736(04)17113-4.
3
New anticoagulants.
Blood. 2005 Jan 15;105(2):453-63. doi: 10.1182/blood-2003-12-4195. Epub 2004 Jun 10.
4
Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial.
Ann Intern Med. 2004 Jun 1;140(11):867-73. doi: 10.7326/0003-4819-140-11-200406010-00007.
5
Inhibition of thrombin-induced feedback activation of factor V: a potential pathway for inhibition of thrombin generation by melagatran.
Blood Coagul Fibrinolysis. 2004 Jan;15(1):25-30. doi: 10.1097/00001721-200401000-00005.
6
Comparison of the effect of fondaparinux and enoxaparin on thrombin generation during in-vitro clotting of whole blood and platelet-rich plasma.
Blood Coagul Fibrinolysis. 2004 Mar;15(2):149-56. doi: 10.1097/00001721-200403000-00006.
7
Assessment of three chromogenic and one clotting assays for the measurement of synthetic pentasaccharide fondaparinux (Arixtra) anti-Xa activity.
J Thromb Haemost. 2004 Feb;2(2):346-8. doi: 10.1111/j.1538-7933.2004.0584a.x.
8
Recombinant factor VIIa partially reverses the inhibitory effect of fondaparinux on thrombin generation after tissue factor activation in platelet rich plasma and whole blood.
Thromb Haemost. 2004 Mar;91(3):531-7. doi: 10.1160/TH03-07-0483.
9
Recombinant factor VIIa reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers.
Br J Haematol. 2004 Mar;124(5):653-8. doi: 10.1111/j.1365-2141.2003.04811.x.
10
A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation.
J Thromb Haemost. 2004 Jan;2(1):47-53. doi: 10.1111/j.1538-7836.2003.00516.x.
Zotero 插件